The buyback machine at Munich Re shows no signs of slowing. Between July 29 and August 6, the reinsurer snapped up 69,928 of its own shares — a clear indication that management’s conviction in the stock remains intact, even as the company wrestles with a softening pricing environment that has forced it to walk back its revenue guidance.
A Two-Billion-Euro Trim
The headline adjustment came last Friday, when CEO Christoph Jurecka lowered the 2026 revenue target for the reinsurance division to €38 billion — €2 billion below the previous plan. The culprit: further price concessions at the latest round of contract renewals. Yet Jurecka was quick to reaffirm that the group remains “on a very good path” toward its full-year profit goal of €6.3 billion.
That confidence is backed by a solid set of second-quarter numbers. The reinsurer earned roughly €2.2 billion in the quarter, up more than six percent year on year, helped by unusually low major losses in its property and casualty book and strong returns from its equity portfolio. Earnings per share climbed to €17.50 from €15.94, while revenue rose 6.38 percent to €18.64 billion. For the first half as a whole, profit reached €3.93 billion, up from €3.18 billion in the prior-year period.
The broader picture is one of higher earnings but capped revenue expectations — a combination that explains why the shares came under pressure following the release. The stock now trades at around €513.40, roughly 10.7 percent below its 52-week high of €575.40 set in October, and sits about 1.3 percent under its 200-day moving average of €520.40. Since the start of the year, the shares are down 8.7 percent.
New Business in the US
Amid the pricing debate, Munich Re continues to expand its biometric risk operations. Manulife Financial Corporation has agreed to transfer the biometric risk on a block of long-term care policies — with reserves of $3.2 billion — to Munich American Reassurance Company, the group’s US subsidiary. The transaction is expected to close in the fourth quarter, subject to regulatory approvals. Deals of this kind are increasingly viewed as a growth area for reinsurers, though they also bring fresh risk considerations at a time when catastrophe losses are trending higher.
Should investors sell immediately? Or is it worth buying Münchener Rück?
Analysts Split on the Path Forward
The analyst community remains divided on where the stock goes from here. Berenberg maintained its “Hold” rating on Monday with a price target of €565, a level that sits comfortably above the current share price and implies residual upside. RBC Capital Markets, by contrast, confirmed a “Sector Perform” stance on August 7 with a target of €500 — below where the stock currently trades. The DZ Bank reiterated its buy recommendation on August 10, albeit without a fresh price target.
Metzler, meanwhile, has already flagged persistent pricing pressure extending into fiscal 2027, suggesting this is not a fleeting issue but something more structural. That raises a critical question for investors: can Munich Re hold its €6.3 billion profit forecast if premium prices in the reinsurance business keep sliding? The answer may hinge on the investment result, which has so far proven a reliable counterweight to shrinking premium margins.
Insider Buying and a Shifting Shareholder Base
Adding a layer of nuance to the picture, recent insider purchases have caught the market’s attention. Both Mari-Lizette Malherbe and Andrew Buchanan acquired shares in the company, according to mandatory disclosures — a move investors often interpret as a vote of confidence from within.
On the other side of the ledger, French asset manager Amundi has trimmed its position, dipping below the three percent regulatory notification threshold. A filing dated August 3 showed its stake at 2.97 percent. Whether that reflects a strategic repositioning or simple portfolio management remains unclear, though it fits a broader pattern of institutional caution.
What to Watch
For now, the technical picture is relatively neutral. The stock sits just under four percent above its 50-day average of €494.53, and the RSI reading of around 52.8 signals neither overbought nor oversold conditions. The next real test will come with the upcoming quarterly reports, which should reveal whether the softening in reinsurance pricing is stabilizing or accelerating. If the investment result continues to act as a buffer, the confirmed profit target looks achievable — and the shares may hold their ground near their moving averages. If pricing pressure intensifies, the gap to that October high could widen rather than close.
Ad
Münchener Rück Stock: Buy or Sell?! New Münchener Rück Analysis from August 12 delivers the answer:
The latest Münchener Rück figures speak for themselves: Urgent action needed for Münchener Rück investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 12.
Münchener Rück: Buy or sell? Read more here...
